Navigation Links
Ruxolinitib better at reducing myelofibrosis symptoms, study shows
Date:12/12/2011

SAN DIEGO -- In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss. The results were presented today at the annual meeting of the American Society of Hematology and Oncology in San Diego.

Myelofibrosis is a bone marrow disorder that disrupts the body's normal production of blood cells, resulting in extensive scarring in the bone marrow. Patients tend to be over age 50.

"For years, researchers have struggled to find effective medications to help patients struggling with symptoms of this chronic pre-leukemia condition," says lead investigator Ruben Mesa, M.D., of Mayo Clinic in Arizona. There are several thousand new myelofibrosis patients in the U.S. every year.

Only about 10 percent of myelofibrosis patients are eligible for a bone marrow transplant and chemotherapy often falls short, Dr. Mesa says. A handful of off-label chemotherapy drugs have been modestly helpful, he says.

A randomized, double-blind clinical trial, known as the COMFORT-1 study, showed that ruxolinitib reduced spleen size by more than 35 percent in almost all of the 154 patients studied. An enlarged spleen, caused by sequestered over-proliferating blood cells, causes discomfort and can also lead to the need for blood transfusions and further medical complications for patients.

In the study, patients treated with ruxolinitib also reported less severe symptoms than those reported by patients treated with a placebo.

A tandem randomized investigation in Europe, known as the COMFORT-2 study, showed that ruxolinitib also was more effective at reducing symptoms than the best available chemotherapies -- specifically, the off-label drugs doctors have been offering.

"The studies confirmed the drug is very effective. As a representative of a particular class of molecular inhibitors called JAK2 inhibitors, which are now being widely studied, ruxolinitib suggests this category will continue to be promising for myelofibrosis," Dr. Mesa says. Most surprising for researchers, however, was the ultimate comparison between the two clinical trials.

"When we looked at the control arms of the two studies we found that the best available chemotherapies we've been using up to this time are no more effective than a placebo," Dr. Mesa says. The comparison provided a wake-up call, he adds. "This was a unique piece of information we hadn't had in the past, and it offers further incentive and pressure to find better therapies for patients."


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Autism-Related Hypersensitivity Better Understood
2. Developing guidelines for better reporting of health research
3. Hawaiian-shirt.net Offers 10 Tips To Beat The Winter Blues: Things You Can Do Right Now to Have a Better Day
4. Better care at any hour for palliative patients
5. Patients Do Better at Hospitals That Follow Stroke Guidelines
6. More Expensive Hospital Care May Not Mean Better
7. New MRI May Lead to Better Brain Pictures
8. Biological clock could be a key to better health, longer life
9. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
10. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
11. New approach to immune cell analysis seen as first step to better distinguish health and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: